What is the clinical evidence from this study?

Study design: Review. Population: Diabetic nephropathy. Intervention: Combination antihypertensive therapy (ACE-I and AIIR or CCB) vs. Monotherapy.

What does this research mean for the field?

Combination therapy with ACE inhibitors and angiotensin II receptor blockers shows inconsistent synergistic effects on proteinuria and hypertension in patients with diabetic nephropathy, and should currently be reserved for patients unresponsive to monotherapy or other combinations. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To review the efficacy of combination antihypertensive therapies, particularly dual renin-angiotensin system inhibition and calcium channel blocker combinations, in treating diabetic nephropathy and achieving strict blood pressure targets.

June 1, 2002Diabetes Technology & Therapeutics

Combination Antihypertensive Therapy in the Treatment of Diabetic Nephropathy

View Full Paper

Ask AI

Bookmark

Key result

Combination therapy with ACE inhibitors and angiotensin II receptor blockers showed inconsistent synergistic effects on proteinuria and hypertension in patients with diabetic nephropathy.

Why the study?

Does combination antihypertensive therapy improve blood pressure and proteinuria in patients with diabetic nephropathy?

Population

Patients with diabetic nephropathy and hypertension

Comparison

Combination antihypertensive therapy vs Monotherapy

Design

Review

Authors

GBGeoffrey BonerTel Aviv University ZCZemin CaoBaker Heart and Diabetes Institute MCMark E. CooperUniversité Claude Bernard Lyon 1

Discussion

Member takes

Implication

Cautious use only in refractory cases; leaves open whether consistent synergy exists beyond monotherapy.

Key Points

To review the efficacy of combination antihypertensive therapies, particularly dual renin-angiotensin system inhibition and calcium channel blocker combinations, in treating diabetic nephropathy and achieving strict blood pressure targets.
Narrative review synthesizing preclinical animal data and human clinical trials evaluating monotherapy versus combination antihypertensive regimens in diabetic and nondiabetic renal disease.
Achieving guideline-recommended target blood pressure levels (130/80 mm Hg for proteinuria ≤1 g/day; 125/75 mm Hg for proteinuria >1 g/day) typically requires two or more antihypertensive agents.
Combining ACE inhibitors with angiotensin II receptor blockers or calcium channel blockers provides synergistic reductions in proteinuria and blood pressure in some models, though trial findings remain variable.
Dual renin-angiotensin blockade represents an effective therapeutic option for patients with persistent proteinuria or hypertension refractory to single-agent therapy.

Structured PICO

Does combination antihypertensive therapy improve blood pressure and proteinuria in patients with diabetic nephropathy?

Population

Patients with diabetic nephropathy and hypertension

Intervention

Combination antihypertensive therapy (ACE-I + AIIR or ACE-I + calcium channel blockers)

Comparator

Monotherapy

Outcome

Reduction in blood pressure and proteinuriasurrogate

Combination therapy with ACE-I and AIIR may be considered in diabetic nephropathy patients whose hypertension or proteinuria does not respond to monotherapy, though evidence of synergistic benefit remains inconsistent.

Limitations

Results have not been consistent in all studies
Additional studies are needed to provide more convincing evidence

Cite This Study

Boner et al. (2002) conducted a review in Diabetic nephropathy. Combination antihypertensive therapy (ACE-I and AIIR or CCB) vs. Monotherapy was evaluated. Combination therapy with ACE inhibitors and angiotensin II receptor blockers showed inconsistent synergistic effects on proteinuria and hypertension in patients with diabetic nephropathy.

synapsesocial.com/papers/6a1d848aba65f5ee325e85aa https://doi.org/10.1089/152091502760098456

View Full Paper

Ask AI

Bookmark

Combination Antihypertensive Therapy in the Treatment of Diabetic Nephropathy

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Combination Antihypertensive Therapy in the Treatment of Diabetic Nephropathy

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Also Consider

Also Consider